Targets › GLA
5 programs from 5 companies in 8 trials: 3 Phase 1, 2 Phase 2, 2 Phase 3, 1 Phase 4; Metabolic and endocrine, Genitourinary; next expected readout Dec 2026.
Catalyzes the hydrolysis of glycosphingolipids and participates in their degradation in the lysosome. (UniProt, P06280)
Open in Phaseline: the race on GLA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Replagal alpha-galactosidase A (agalsidase alfa) enzyme replacement therapy | GLA | Phase 4 | Fabry Disease | Oct 2027 |
| Amicus Therapeutics | Migalastat Alpha-galactosidase A stabiliser | GLA | Phase 3 | Fabry Disease | Dec 2026 |
| Chiesi Farmaceutici | PRX-102 Recombinant human alpha galactosidase-A (pegunigalsidase alfa) | GLA | Phase 2 | Fabry Disease | Oct 2027 |
| UniQure Biopharma | AMT-191 AAV5-based gene therapy delivering human α-galactosidase A | GLA | Phase 1 | Fabry Disease | Dec 2027 |
| 4D Molecular Therapeutics | 4D-310 AAV gene therapy encoding codon-optimized human GLA transgene | GLA | Phase 1 | Fabry Disease | Jun 2030 |
Fabry Disease (8)
protein or peptide (3), small molecule (2)
UniQure Biopharma (1) Chiesi Farmaceutici (1) Amicus Therapeutics (1) Takeda (1) 4D Molecular Therapeutics (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.